Skip to main content

Advertisement

SpringerLink
Log in

DEMENTIA

The phosphorylation cascade hypothesis of Alzheimer’s disease

  • News & Views
  • Published:

From Nature Aging

View current issue Submit your manuscript

Alzheimer’s disease (AD) is characterized by amyloid-β (Aβ)-induced phosphorylation of the axon-stabilizing tau protein, which causes neurodegeneration. Here, Morshed et al. show that deregulated phosphorylation in AD also affects other proteins and cell types in the brain, suggesting that the tau-centric view on Aβ toxicity should be revised.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Kinome map of all kinases with phosphopeptides that were significantly associated with tau or oligodendrocyte cluster centroids.

References

  1. Johnson, E. C. B. et al. Nat. Med. 26, 769–780 (2020).

    Article  CAS  Google Scholar 

  2. Wesseling, H. et al. Cell 183, 1699–1713 (2020).

    Article  CAS  Google Scholar 

  3. Morshed, N. et al. Nat. Aging https://doi.org/10.1038/s43587-021-00071-1 (2021).

  4. Wu, J., Bie, B., Foss, J. F. & Naguib, M. Mol. Neurobiol. 57, 2290–2300 (2020).

    Article  CAS  Google Scholar 

  5. Dujardin, S., Colin, M. & Buee, L. Neuropathol. Appl. Neurobiol. 41, 59–80 (2015).

    Article  CAS  Google Scholar 

  6. De Strooper, B. & Karran, E. Cell 164, 603–615 (2016).

    Article  Google Scholar 

Download references

Acknowledgements

Work in the authors’ laboratories is supported by the Swedish Research Council, the European Research Council, Swedish State Support for Clinical Research (ALFGBG), the Knut and Alice Wallenberg Foundation, and UK Dementia Research Institute at UCL. H.Z. is a Wallenberg Scholar.

Author information

Authors and Affiliations

  1. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

    Gunnar Brinkmalm & Henrik Zetterberg

  2. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

    Gunnar Brinkmalm & Henrik Zetterberg

  3. Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK

    Henrik Zetterberg

  4. UK Dementia Research Institute at UCL, London, UK

    Henrik Zetterberg

Authors
  1. Gunnar Brinkmalm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henrik Zetterberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Gunnar Brinkmalm or Henrik Zetterberg.

Ethics declarations

Competing interests

H.Z. has served at scientific advisory boards for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside of submitted work). G.B. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brinkmalm, G., Zetterberg, H. The phosphorylation cascade hypothesis of Alzheimer’s disease. Nat Aging 1, 498–499 (2021). https://doi.org/10.1038/s43587-021-00077-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43587-021-00077-9

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation